Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | L3MBTL3 | Q96JM7 | 4/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | MBTD1 | Q05BQ5 | 3/20 | 0.38 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL737910 | 1.00 | KDM4E (0.44) | KDM4EALDH1A1CYP2C19ALOX15CYP3A4 | |
| SCHEMBL14175057 | 1.00 | KDM4E (0.44) | KDM4EALDH1A1CYP2C19ALOX15CYP3A4 | |
| SCHEMBL3688411 | 1.00 | KDM4E (0.44) | KDM4EALDH1A1CYP2C19ALOX15CYP3A4 | |
| SCHEMBL9557835 | 0.97 | KDM4E (0.46) | KDM4EALDH1A1CYP2C19ALOX15CYP3A4 | |
| SCHEMBL736959 | 0.97 | KDM4E (0.46) | KDM4EALDH1A1CYP2C19ALOX15CYP3A4 | |
| SCHEMBL736459 | 0.97 | KDM4E (0.46) | KDM4EALDH1A1CYP2C19ALOX15CYP3A4 | |
| SCHEMBL14313611 | 0.92 | KDM4E (0.46) | KDM4EALDH1A1CYP2C19ALOX15CYP3A4 | |
| SCHEMBL13342157 | 0.92 | KDM4E (0.46) | KDM4EALDH1A1CYP2C19ALOX15CYP3A4 | |
| SCHEMBL20245295 | 0.92 | KDM4E (0.46) | KDM4EALDH1A1CYP2C19ALOX15CYP3A4 | |
| SCHEMBL22447170 | 0.90 | ALDH1A1 (0.46) | KDM4EALDH1A1CYP2C19ALOX15CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130245013-A1 | STORAGE STABLE PERFUSION SOLUTION FOR DIHYDROPTERIDINONES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-09-19 | — | — | US | disclosed |
| US-8445675-B2 | Storage stable perfusion solution for dihydropteridinones | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-05-21 | — | — | US | disclosed |
| US-8445675-B2 | Storage stable perfusion solution for dihydropteridinones | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-05-21 | — | — | US | disclosed |
| US-20120107312-A1 | Combinations for the Treatment of Diseases involving Cell Proliferation | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-03 | — | — | US | disclosed |
| US-8143247-B2 | Combinations for the treatment of diseases involving cell proliferation | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-03-27 | — | — | US | disclosed |
| US-8138341-B2 | Intermediate compounds useful for the manufacture of dihydropteridinones | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-03-20 | — | — | US | disclosed |
| US-8138373-B2 | Process for the manufacture of dihydropteridinones | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-03-20 | — | — | US | disclosed |
| US-8058270-B2 | Dihydropteridinones for the treatment of cancer diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-15 | — | — | US | disclosed |
| US-8003786-B2 | Dihydropteridinone compounds | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2011-08-23 | — | — | US | disclosed |
| US-20100324288-A1 | Dihydropteridinone Compounds | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2010-12-23 | — | — | US | disclosed |
| US-7750152-B2 | Intermediate compounds for making dihydropteridinones useful as pharmaceutical compositions and processes of making the same | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2010-07-06 | — | — | US | disclosed |
| US-20090238828-A1 | Combinations for the Treatment of Diseases involving Cell Proliferation | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-09-24 | — | — | US | disclosed |
| US-20090143379-A1 | Storage stable perfusion solution for dihydropteridinones | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-06-04 | — | — | US | disclosed |
| US-20080293944-A1 | Piperazinyl Compounds | ONCOHEROES BIOSCIENCES INC. | 2008-11-27 | — | — | US | disclosed |
| US-20080221099-A1 | DIHYDROPTERIDINONES FOR THE TREATMENT OF CANCER DISEASES | ONCOHEROES BIOSCIENCES INC. | 2008-09-11 | — | — | US | disclosed |
| US-20080177066-A1 | Process for the manufacture of dihydropteridinones | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-07-24 | — | — | US | disclosed |
| US-20080171747-A1 | Intermediate Compounds for making Dihydropteridinones Useful as Pharmaceutical Compositions | ONCOHEROES BIOSCIENCES INC. | 2008-07-17 | — | — | US | disclosed |
| US-20080081817-A1 | Nitrogenous Fused Bicyclic Compound | TANABE SEIYAKU CO., LTD. (JP) | 2008-04-03 | — | — | US | disclosed |
| US-20080081817-A1 | Nitrogenous Fused Bicyclic Compound | TANABE SEIYAKU CO., LTD. (JP) | 2008-04-03 | — | — | US | disclosed |
| EP-1772454-A1 | NITROGENOUS FUSED BICYCLIC COMPOUND | TANABE SEIYAKU CO., LTD. (JP) | 2007-04-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324288-A1 | Dihydropteridinone Compounds | QDPR, DHPS, DHFR | KDM4E 4368/4885ALDH1A1 1055/4885CYP2C19 209/4885 |
| US-20080221099-A1 | DIHYDROPTERIDINONES FOR THE TREATMENT OF CANCER DISEASES | PLK4, TK1, POLK | KDM4E 4546/4885ALDH1A1 3183/4885CYP2C19 2078/4885 |
| US-20120107312-A1 | Combinations for the Treatment of Diseases involving Cell Proliferation | CCNA1, MKI67, CCNA2 | KDM4E 4564/4885ALDH1A1 1053/4885CYP2C19 3291/4885 |
| US-20090238828-A1 | Combinations for the Treatment of Diseases involving Cell Proliferation | CCNA1, MKI67, CCNA2 | KDM4E 4564/4885ALDH1A1 1053/4885CYP2C19 3291/4885 |
| US-20090143379-A1 | Storage stable perfusion solution for dihydropteridinones | QDPR, F5, F12 | KDM4E 4832/4885ALDH1A1 1200/4885CYP2C19 301/4885 |
| US-20080171747-A1 | Intermediate Compounds for making Dihydropteridinones Useful as Pharmaceutical Compositions | QDPR, DHPS, DHODH | KDM4E 4469/4885ALDH1A1 759/4885CYP2C19 73/4885 |
| US-20080177066-A1 | Process for the manufacture of dihydropteridinones | QDPR, DHPS, DHODH | KDM4E 3687/4885ALDH1A1 731/4885CYP2C19 274/4885 |
| US-20130245013-A1 | STORAGE STABLE PERFUSION SOLUTION FOR DIHYDROPTERIDINONES | QDPR, F5, F12 | KDM4E 4832/4885ALDH1A1 1200/4885CYP2C19 301/4885 |
| US-20080293944-A1 | Piperazinyl Compounds | QDPR, DHPS, DPYD | KDM4E 4088/4885ALDH1A1 709/4885CYP2C19 75/4885 |
| US-20080081817-A1 | Nitrogenous Fused Bicyclic Compound | KCNH2, KCNN2, KCNN1 | KDM4E 2939/4885ALDH1A1 3215/4885CYP2C19 1550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.